• WCG’s eCOA portfolio and imaging analysis technology from NeuroRx are now part of Clario!

menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • Study Endpoints
        • Cardiac safety and efficacy endpoint solutions for all phases, anywhere in the world.

        • Collect continuous ECG data in site-based or hybrid trials with our flexible solutions and patient-friendly devices.

        • Collect and centrally analyze accurate, consistent, quality blood pressure data from site-based to hybrid trials.

        • Monitor every heartbeat with precision to assess safety and efficacy throughout your site-based or hybrid clinical trial.

        • Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial.

        • Leverage our key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.

        • Make your clinical trials easier, faster, more engaging and accessible to all.

        • Enjoy flexible, fast and confidential site assessments at home.

        • Enhance your ePRO data with photo and audio capture.

        • Accelerate your clinical trial setup with Clario’s pre-validated and configured eCOA assessments.

        • Improve data accuracy and reduce variability in scoring with Clario’s training solutions.

        • Your trusted partner for the richest eCOA endpoint data in your clinical trial.

        • Monitor Suicide Ideation and Behavior (SIB) in clinical trials effectively with Clario’s suicide assessment tool, eC-SSRS.

        • Accelerate drug development and reduce risk with Clario’s comprehensive medical imaging core lab services.

        • The Clario team includes medical imaging experts and globally recognized key opinion leaders (KOLs) representing multiple disciplines.

        • Clario’s Image Redact AI automatically redacts sensitive patient identifiers from videos, photos and PDFs.

        • Secure accurate results, streamline your processes, and meet your unique needs with our imaging platform.

        • Leverage our full range of medical imaging and diagnostic imaging modalities, including CT Scans, Endoscopy, MRIs, and more.

        • Securely collect, store, and share de-identified images for compliance with 21 CFR Part 11 and EU GDPR standards.

        • Clario's complete solution for measuring objective digital endpoints of mobility with wearable sensor technology.

        • The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights.

        • Explore more than 750 scientific publications that reflect the technical and clinical applications of Clario’s Opal® System.

        • Everything you need for high quality, low variability pulmonary function data and high patient compliance for clinical trials.

        • Centralized, on-site pulmonary function testing for clinical trials.

        • Remote spirometry testing for respiratory clinical trials.

        • Assess cough frequency, cough severity and other lung sounds such as crackles or rhonchi for clinical trials.

        • Assess the capacity of the lungs for effective gas transfer.

        • Advanced, cloud-native technologies and clinical trial software to screen, clean, QC and assess complicated data.

        • Collect, centralize and manage participant screening and eligibility data with customized workflows.

        • Boost stakeholder insights with business intelligence (BI) tools, analytics for endpoint and safety risks, and data exchange solutions.

        • Securely collect, store and share compliant images in the cloud to keep clinical trial sponsors and labs informed.

    • Segments
    • Study Phases
    • Technology
  • Therapeutic Areas
    • Cardiovascular & Metabolic Icon RGBCardiovascular & Metabolic
    • Dermatology Icon RGBDermatology
    • Type 2 Diabetes and Obesity iconDiabetes and Obesity
    • Gastroenterology Icon RGBGastroenterology
    • Hepatology Icon RGBHepatology
    • Infectious Disease Icon RGBInfectious Diseases
    • Muskoskeletal Icon RGBMusculoskeletal
    • Neuroscience Icon RGBNeuroscience
      • Neuroscience Indications
    • Oncology Icon RGBOncology
    • Ophthalmology Icon RGBOphthalmology
    • Respiratory Solutions IconRespiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rapid Start
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)
    • Cardiac Solutions
      • Cardiac Solutions
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Imaging Platform
      • Modalities
      • SMART Submit
    • Precision Motion
      • Precision Motion for Clinical Trials
      • Precision Motion for Research
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, and more.)
      • Virtual Home Spirometry
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Hybrid Trials
    • Biotechs
    • CROs
    • Pharma
    • Phase I
    • Phase II/III
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology
    • Ophthalmology
    • Type 2 Diabetes and Obesity
    • Respiratory Solutions
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home Resources Blog Articles Revolutionizing Ulcerative Colitis Assessment

Revolutionizing Ulcerative Colitis Assessment

How AI-powered endoscopy review improves accuracy and efficiency

Marcela Vieira Fleury Curado, M.D. – Medical Director, Gastroenterology at Clario

In the evolving landscape of gastroenterology, artificial intelligence (AI) is transforming the accuracy and efficiency of endoscopic assessments, particularly in ulcerative colitis (UC) clinical trials. Central reading – where expert gastroenterologists evaluate colonoscopy videos using scoring systems like the Mayo Endoscopic Subscore (MES) – is essential for assessing disease severity consistently. However, manual review is both time-consuming and prone to variability among readers, leading to inefficiencies and inconsistencies in interpretation.

A joint effort by researchers from Clario and Atrius Health has led to a study that demonstrates how AI-powered frame detection can streamline endoscopic video review, reduce workload, and improve grading consistency. This innovative system automates the identification of the most relevant frames, allowing gastroenterologists to focus on key video segments, speed up assessments, and make more reliable clinical decisions. By filtering non-informative frames, AI not only enhances the accuracy of disease grading but also reduces the time burden and fatigue on clinicians, making UC clinical trials more efficient and effective for both researchers and patients.

The challenge of manual MES scoring

Assessing UC severity accurately involves meticulous review of colonoscopy videos, but the process is troubled by inefficiencies.

Primary issues include:

  • High inter-reader variability: Different gastroenterologists may interpret the same degree of severity differently, leading to inconsistencies in grading.
  • Time-intensive review process: Hours of video footage must be manually examined to determine disease severity, a relatively high-workload process.
  • Non-informative frames: Portions of these videos often contain uninformative segments, including blurry frames, out-of-body views, or obstructed visuals, which slow down review without contributing to meaningful assessment.

Addressing these challenges requires a method to automatically highlight the most relevant video frames while filtering out non-informative segments.

AI-powered frame detection: A more efficient approach

Researchers developed an AI system capable of automatically detecting and prioritizing informative frames from endoscopic videos. The system, trained utilizing an aggregated dataset of over 100,000 annotated endoscopic frames, uses neural networks to identify and remove unhelpful video segments, and in doing so, enhancing the efficiency of UC grading.

A key feature of this system is its temporal smoothing module, which evaluates entire videos by analyzing frame-by-frame. This ensures that only the most relevant frames – those that truly reflect disease severity- or the absence of it– are presented for assessment.

To evaluate its effectiveness, the AI model was tested on a large aggregate dataset consisting of 1,564 UC patients and a total 357 hours of video footage.

The findings showed:

  • 80.02% accuracy in detecting non-informative frames
  • 3:09 minutes average reduction per video by filtering uninformative segments
  • 83 total hours saved across the dataset
  • 77.61% mean video informativeness level (mVIL), indicating that most retained frames provided meaningful diagnostic information

Boosting the accuracy of automated disease scoring

In addition to saving time, AI-powered frame selection can improve the performance of automated MES grading. The system was evaluated by comparing AI-predicted scores with those from expert gastroenterologists. Results showed a high correlation between AI-generated MES scores and human assessments, both in the full dataset and when central and local readings aligned.

The metric used to assess scoring agreement was Quadratic Weighted Kappa (QWK), which measures how closely AI-generated scores matched expert assessments.

The impact of AI-driven filtering on QWK was as follows:

Swipe left to scroll table.

Video TypeBefore AI FilteringAfter AI FilteringImprovement
Full-Length Videos0.6660.690+0.024
Concordant Readings0.7060.725+0.019
Adjudicated Readings0.6150.646+0.031

The data confirms that removing non-informative frames enhances the accuracy of AI-assisted disease grading. Even small improvements in QWK translate into more consistent and reliable UC assessments, benefiting clinical trials and patient care.

Reducing reviewer fatigue and enhancing workflow

The introduction of AI-powered frame detection is not just about improving accuracy—it also reduces fatigue among gastroenterologists. Physicians reviewing endoscopic videos must maintain high levels of focus to ensure consistent, accurate grading.  Unnecessary exposure to irrelevant footage could contribute to mental strain and variability in assessments.

By trimming videos to focus only on essential frames, AI enhances both the efficiency and quality of clinical evaluations. This allows gastroenterologists to allocate more focus to complex cases rather than sifting through redundant footage. The AI system can be integrated into the central reading platform, streamlining video review by optionally enabling the automated filtering of non-assessable intervals.

The future of AI in gastroenterology

AI-supported video analysis represents a significant leap forward in UC clinical trials, but its implications extend beyond just this field. Similar AI frameworks can be applied to other gastrointestinal conditions that rely on endoscopic evaluation, such as Crohn’s disease or colorectal cancer.

Moreover, as AI models continue to learn from larger and more diverse datasets, their accuracy and efficiency will improve, further refining the role of AI-assisted assessments in gastroenterology.

The successful implementation of AI-powered informative frame detection in UC trials paves the way for broader adoption of AI in clinical workflows. By enhancing accuracy and improving efficiency, AI is set to redefine the future of disease assessment and treatment planning.

Learn more about how Clario is leading the AI revolution in clinical trials.

Read more about Clario’s use of AI
Back to articles
Share
Twitter Facebook LinkedIn

Latest articles

See all articles
Article

Researcher spotlight: Dr. Lauren Tueth

Precision Motion

Read
Article

Researcher spotlight: Brice Cleland

Precision Motion

Read
Article

Researcher spotlight: Josefa Domingos

Precision Motion

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2025 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum